Skip to search formSkip to main contentSkip to account menu

conivaptan

Known as: 4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide, 4''-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide, (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)- 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

BenzazepinesVasopressin Antagonist

Narrower (3)

Conivaptan hydrochlorideVaprisolYM 087

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Therapeutic Effect of Conivaptan Bolus Dosing in Hyponatremic Neurosurgical Patients
To determine the natremic response of a single 20‐mg bolus dose of conivaptan, an arginine vasopressin antagonist, in… 
2013
2013
Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals.
Hyponatremia is the most common electrolyte abnormality encountered in clinical practice, but its optimal management is still… 
2012
2012
Initial experience with conivaptan use in critically ill infants with cardiac disease.
OBJECTIVE Arginine vasopressin (AVP) is the primary regulator of free water retention through its interactions with the AVP type… 
2008
2008
Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH
The available treatment options for hyponatremia secondary to SIADH are limited and not completely effective. Conivaptan is a… 
Review
2008
Review
2008
Mechanisms, Risks, and New Treatment Options for Hyponatremia
Hyponatremia is the most common electrolyte abnormality in hospitalized patients and is associated with increased mortality… 
Review
2008
Review
2008
Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia
The treatment of hyponatremia, especially euvolemic and hypervolemic hyponatremia, has changed with the development of drugs… 
Review
2006
Review
2006
Hyponatremia and heart failure--treatment considerations.
Hyponatremia as it occurs in the heart failure patient is a multifactorial process. The presence of hyponatremia in the heart… 
2005
2005
Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
To find a new series of arginine vasopressin (AVP) V1A receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4… 
Highly Cited
2003
Highly Cited
2003
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
BACKGROUND Exercise intolerance is a primary characteristic of chronic congestive heart failure. Exercise testing is therefore… 
2002
2002
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)